Matches 1 - 50 out of 71 1 2 >


Match Document Document Title
US20050226929 Controlled release opioid analgesic formulation  
A pharmaceutical sustained release formulation for opioid analgesics which can be administered every 12 hours for control of pain in patients suffering from chronic pain.
US20130209561 ABUSE-RESISTANT OPIOID DOSAGE FORM  
We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.
US20110142933 Controlled Release Dosage Form of Tacrolimus  
A controlled release dosage form of tacrolimus, comprising a solid dispersion of tacrolimus, wherein a controlled release base, which is selected from the group consisting of a water-soluble...
US20110123613 EXTENDED-RELEASE DOSAGE FORM  
Provided are pharmaceutical formulations comprising sustained release particles each having an inner core bead comprising an active pharmaceutical ingredient an intermediate coating substantially...
US20150010625 Low Dose Topiramate/Phentermine Composition and Methods of Use Thereof  
A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in...
US20140037723 Low Dose Topiramate/Phentermine Composition And Methods Of Use Thereof  
A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in...
US20150072005 ASPIRIN FORMULATION FOR INCREASED EFFICACY  
Provided are methods for enhancing the efficacy of aspirin. Also provided are methods for reducing pain or preventing or treating heart attack, stroke or blood clot in a subject in need thereof....
US20120282336 BILAYER TABLET FORMULATIONS  
The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation...
US20060078615 Bilayer tablet of telmisartan and simvastatin  
A bilayer tablet comprises a first layer formulated for instant release of the angiotensin II receptor antagonist telmisartan from a dissolving tablet matrix and a second layer formulated for...
US20070036860 Treatment of allergic conditions  
Orally administered sodium cromoglycate has been found to be effective in the treatment of allergic conditions such as asthma, general food allergies, ulcerative colitis, atopic eczema, chronic...
US20090280173 Multilayer Omeprazole Tablets  
Multilayer tablets of Omeprazole and/or a salt thereof essentially bioequivalent in terms of plasma Omeprazole Cmax and AUC to Omeprazole capsules and/or Omeprazole Magnesium tablets consisting of...
US20100183713 GASTROINTESTINAL-SPECIFIC MULTIPLE DRUG RELEASE SYSTEM  
The present invention provides compositions and methods for the multiple release of a drug in the gastrointestinal tract of a subject through the use of an oral multiple drug release system. The...
US20150079169 CONTROLLED DOSING OF CLOPIDOGREL WITH GASTRIC ACID INHIBITION THERAPIES  
The present invention provides for novel formulations of clopidogrel in combination with proton pump inhibitors (PPI) and optionally with NSAIDs, for use as improved antiplatelet therapies in...
US20050084531 Tablet with aqueous-based sustained release coating  
A tablet core containing a water-soluble, preferably highly water-soluble, active ingredient is coated for sustained release with an aqueous-based coating of an ethyl acrylate-methyl methacrylate...
US20150125524 PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDS  
The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The...
US20140212489 PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDS  
The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The...
US20140141080 PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDS  
The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The...
US20130078304 CONTROLLED RELEASE FORMULATION FOR TREATING SLEEP DISORDERS  
The invention relates to a controlled-release formulation for preventing and/or treating sleep disorders comprising Zaleplon or a pharmaceutically acceptable salt thereof in immediate release form...
US20110123612 PHARMACEUTICAL PREPARATION CONTAINING NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-2 RECEPTOR BLOCKER  
The present invention provides a pharmaceutical formulation comprising an immediate-release compartment containing an angiotensin-2 receptor blocker (ARB) as a pharmacologically active ingredient...
US20100285125 DELIVERY SYSTEM FOR POORLY SOLUBLE DRUGS  
The present invention relates to an oral drug delivery system for poorly soluble drugs, which can provide sustained near zero order release of poorly water soluble drugs from erodible matrix...
US20050214369 Lecithin-containing granular compositions and methods of their preparation  
Methods of preparing granular compositions containing lecithin, preferably as a major or sole ingredient, are described. Granular lecithin-containing compositions are also described and can be...
US20110111022 PHARMACEUTICAL FORMULATION  
The present invention provides a pharmaceutical formulation comprising a compartment containing a rennin inhibitor as a pharmacologically active ingredient, and a compartment having an...
US20050249810 Film coating for tablets and caplets  
The present invention relates to novel coating compositions for application to solid dosage forms such as tablets or caplets, solid dosage forms coated with the composition, and methods of...
US20050266078 Compressed tablets comprising microcapsules with modified release  
A multi(micro)particulate tablet is provided comprising microparticles which comprise a mechanically non-deformable core of active principle (AP). The tablet is formed from reservoir microcapsules...
US20110052683 PHARMACEUTICAL PREPARATION FOR TREATING CARDIOVASCULAR DISEASE  
The present invention provides a pharmaceutical preparation comprising a prior-release compartment containing a hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor as a pharmacologically...
US20050003005 Granules containing acid-unstable chemical in large amount  
It is intended to provide preparations such as capsules containing an acid-unstable medicament (in particular, a benzimidazole compound having an antiulcer effect, etc.) at a high concentration...
US20070218134 Compositions Comprising Organic Compounds  
The present invention relates to pharmaceutical compositions for sustained release comprising as active ingredient an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof,...
US20070292511 Duloxetine hydrochloride delayed release formulations  
Delayed release formulations of duloxetine hydrochloride and methods for its manufacture are described. A preferred formulation includes an inert core, a drug layer comprising duloxetine...
US20090041840 Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration  
A novel sleep regulating pharmaceutical formulation is introduced, typically implementing two principal drugs having actions which are reversive to one another, yet incorporated into a unitary...
US20070036858 Drug delivery system for topical administration  
This invention is directed to new drug delivery systems (SMS packaging™) and uses thereof, of freshly prepared, effective, high concentrated, hygienic pharmaceutical compositions. The new delivery...
US20090022797 Stabilized tolterodine tartrate formulations  
A pharmaceutical composition contains tolterodine L-tartrate stabilized against degradation with an acid. Acid-stabilized tolterodine L-tartrate may be used to make various types of immediate...
US20070036859 Sustained release antihistamine and decongestant composition  
A controlled-release, non-sedating antihistamine and decongestant composition which provides a 24-hour decongestant dissolution profile using standard ungranulated xanthan gum as the sole...
US20070248669 Oral sustained release formulation  
The present invention relates to an oral sustained release formulation comprising a core, a medicinal layer containing vanlafaxine or a pharmaceutically acceptable salt of venlafaxine and a...
US20050074494 Itraconazole immediate release formulation  
The present invention relates to active pellets without a specific inert starting seed size and without a seal coat, which may be compressed into a tablet or loaded into a capsule to form an...
US20050152976 Coated particles with prolonged release and tablets containing same  
The invention concerns coated particles with prolonged release, a method for preparing same and multiparticulate tablets comprising said coated particles.
US20070248670 TOLTERODINE BEADS  
Controlled release tolterodine beads are formed of a sugar core, an innermost sealcoat layer comprising HPMC, a tolterodine drug layer, and an outer control release layer. The thickness of the...
US20050089574 New film coating  
A film coating composition suitable for use in coating pharmaceutical formulations to provide modified release comprising a dispersion which includes: a) an acrylic polymer, b) a vinyl acetate...
US20090130206 Controlled Release Compositions of an Antidepressant Agent  
The present invention relates to controlled release compositions comprising an anti-depressant compound. More particularly, the present invention relates to controlled release compositions...
US20070184111 Hybrid tablet  
A hybrid tablet and method are provided. The tablet may have an inner core and an outer layer. The outer layer includes a first agent, the outer layer having a first dissolution rate. The inner...
US20150202147 Modified Release Formulations Of A Bupropion Salt  
The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of...
US20070275060 Extended release solid pharmaceutical composition containing carbidopa and levodopa  
The invention provides a compressed tablet that provides a extended release tablet containing a extended release form of carbidopa and a extended release form of levodopa. The tablet optionally...
US20050042290 Controlled release pharmaceutical formulation containing venlafaxine  
A solid controlled release pharmaceutical formulation for once daily administration comprises a core comprising venlafaxine, polyvinylpyrrolidone, a low viscosity hydrophilic polymer and a high...
US20140004189 MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS MEMANTINE  
Modified release pharmaceutical compositions of memantine or pharmaceutically acceptable salts thereof are described. The compositions of invention are stable, possess improved formulation...
US20050042277 Pharmaceutical compositions having a swellable coating  
A pharmaceutical dosage form containing a pharmaceutical active that is not stable in the presence of acid comprises a core containing the active and a disintegrant, a swellable coating...
US20060073204 Modified release oral pharmaceutical composition  
The present invention relates to a modified release oral pharmaceutical composition comprising a core containing an active ingredient; and a coating surrounding said core, wherein said coating...
US20050089571 Pharmaceutical formulation for the active ingredient budesonide  
The invention relates to a pharmaceutical formulation containing essentially a) an inner layer which can optionally be applied to a core, with the active substance budesonide, bound with a binding...
US20070231385 Controlled Release Pharmaceutical Composition and a Process for Preparing the Same  
A three-drug antiretrovial pharmaceutical composition having a selective combination of a controlled release active formulation and an immediate release active formulation for once daily...
US20090169622 DELAYED-RELEASE ORAL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF COLONIC DISORDERS  
A timed or delayed release oral composition delivery system for the treatment of colonic disorders and diseases is provided. According to one aspect, a delayed release oral pharmaceutical...
US20100172983 Pharmaceutical Compositions for the Coordinated Delivery of Naproxen and Esomeprazole  
The present disclosure is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The...
US20060073205 Controlled release granules comprising porous silica core  
The present invention relates to controlled release granules for medical use comprising a drug loaded porous silica particle, and at least one layer of a controlled release coating material,...

Matches 1 - 50 out of 71 1 2 >